Participated · Seed · Apr 2025

GenrAb discovers and develops naturally occurring, fully‑human neuroprotective antibodies using proprietary immunogenetic models applied to cerebrospinal fluid from patients with active neurological disease. Its lead candidate, TGM‑010, has repeatedly demonstrated the ability to cross the blood‑brain barrier, internalize into neurons, and engage stress‑management machinery to reduce neurological disability. The company says it is building a growing pipeline of partnerable neurotherapeutic antibodies selected for antineuronal capabilities and potential to manage neuronal stress. Proceeds from the announced financing will allow GenrAb to emerge from stealth and accelerate TGM‑010 through IND enabling work toward human clinical studies in 2026. GenrAb was founded on technology exclusively licensed from UT Southwestern Medical Center and is headquartered in BioLabs at Pegasus Park in Dallas. The company has received multiple regional awards recognizing its approach to treating neurodegeneration.

Participated · Series F · Mar 2025

MicroTransponder is a global medical device company focused on research-based neuroscience solutions to restore sensory and motor function for people with neurological conditions. Its FDA-approved Vivistim Paired VNS System is clinically proven to generate improvement in upper limb function for chronic ischemic stroke survivors after six weeks of in-clinic occupational or physical therapy. Vivistim is an implanted device that a therapist pairs with vagus nerve stimulation (VNS) during high-repetition, goal-oriented therapy tasks to increase neuroplasticity. The company says Vivistim helps stroke survivors regain 2–3 times more upper extremity function. MicroTransponder intends to use the new funds to expand operations and its R&D efforts. The company is headquartered in Austin, Texas. MicroTransponder develops research-based neuroscience solutions and is focused on restoring function for people with neurological conditions that impair sensory and motor function. Its core product is the FDA-approved Vivistim Paired VNS System, which pairs vagus nerve stimulation with rehabilitation therapy to improve upper limb function for stroke survivors. The company says Vivistim generates more improvement in upper limb function than rehabilitation alone after six weeks of in-clinic therapy. MicroTransponder intends to use newly raised funds to support market development and commercialization of Vivistim. Leadership includes CEO Richard Foust and newly appointed COO Prashant Rawat, a named inventor on more than 85 patents and patent applications with over 25 years of medical device experience. Rawat’s role will focus on scaling operations to meet commercial demand, securing additional indications for Vivistim, and advancing development of the next-generation Paired VNS Therapy system. MicroTransponder is a Dallas, Texas-based medical device development company led by CEO Frank McEachern. The company develops and continues to expand neurostimulation programs to treat neurological diseases, including post-stroke motor rehabilitation and tinnitus. Its Vivistim® System is designed to treat stroke patients with upper limb deficit and consists of a small implanted battery and wires that connect to the vagus nerve in the neck. During rehabilitative therapy the device delivers a small amount of neurostimulation to the vagus nerve to strengthen neural pathways in the brain. MicroTransponder closed a $5.5M funding round in October 2015. The company intends to use the funds to commercialize its stroke and tinnitus therapies in Europe in 2016 and to complete additional clinical studies. MicroTransponder, Inc. is a Dallas, TX-based medical device company focused on vagus nerve stimulation therapies and wireless pain platforms. It partners with the University of Texas at Dallas to develop vagus nerve stimulation therapy for various neurological disorders. Initial therapeutic targets are stroke, tinnitus, and chronic pain, and its products include the Vivistim System for post-stroke upper-limb deficits and the Serenity® System for tinnitus. The company is led by CEO Frank McEachern. MicroTransponder intends to use new funding to complete three additional clinical trials for stroke and tinnitus and to continue development of its wireless pain platform. The company completed a $3.39M funding round and previously raised $9.6M in 2010. MicroTransponder is a Dallas, Texas-based medical device company developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications. Its initial product is the SAINT™ System for chronic pain. The company announced a $7M Series B financing and was awarded a $2.6M NINDS SBIR FastTrack U44 grant. The grant is a milestone-driven cooperative agreement to support pre-clinical validation of devices for neuropathic pain and manufacturing scale-up. The combined funding has allowed MicroTransponder to hire premier clinical and regulatory expertise and to prepare a series of clinical trials and regulatory filings for the SAINT System. Recent hires include Dr. Evan Rosenfeld as Chief Medical Officer and Vice President of Regulatory Affairs and Brent Tarver as Vice President of Clinical Affairs.

Led · Seed · Feb 2025

Affineon Health, based in Denver, builds an AI-powered inbox that automates routine lab results, prescription renewals, and patient communications to streamline provider workflows. Its flagship solution integrates with electronic health record systems, including athenahealth, and is designed to fit into existing clinician workflows. Affineon reports its tools can reduce inbox volume by up to 80% and save providers more than five hours per week while improving response times and the patient experience. The company has secured partnerships with leading health systems, physician practices, and EHR vendors as evidence of market traction. Affineon recently closed an oversubscribed $5 million seed round and has now raised $6 million in total capital. The new funding is intended to accelerate product development, expand market presence, and deepen its impact on reducing provider administrative burden and burnout.

Led · Convertible Note · Mar 2024

Prolocor is a Philadelphia, PA-based healthcare startup developing a precision diagnostic test that quantifies FcγRIIa (the pFCG test) to predict thrombosis risk. The company's prognostic tool aims to guide treatment decisions by matching therapy intensity to a patient’s risk of events. Led by CEO Dr. Peter DiBattiste and CSO Dr. David Schneider, Prolocor is advancing its clinical program. The company raised $1.7M in bridge funding to support its near-term plans. Prolocor intends to use the funds for its ongoing clinical program and to commercialize the test in 2024. Prolocor is building an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets to assess thrombotic risk. The core product aims to help clinicians match intensity of antithrombotic therapy to individual patient risk, balancing thrombosis and bleeding. The company emphasizes expertise in thrombosis and cardiovascular disease among its founding team. With new funding, Prolocor plans to establish a CLIA-certified laboratory and complete analytical validation of platelet FcγRIIa as a precision tool. Prolocor is also conducting a prospective, observational multicenter non-interventional cohort study of 800 patients who have experienced heart attacks. The company intends to use the funds to move the technology from lab validation toward clinical application.

Participated · Series B · Apr 2023

Recuro Health offers a Digital Medical Home that integrates diagnostic-enabled virtual primary care, virtual behavioral health, at-home lab testing, and genomics alongside care navigation, pharmacy, and care management. The platform combines advanced science, data, at-home diagnostics and targeted genomics (including cancer screening and pharmacogenomics) to inform integrated care. Recuro positions its service as proactive and personalized, aiming to shift care from reactive, disease-focused models to preventive population health. The company plans to use new capital to advance and scale its Digital Medical Home and next-generation digital care services. Its solutions are available nationwide and are used by millions of members. Michael Gorton is CEO and founder, and the company highlights capabilities such as data analytics, quality, and guided referrals. Recuro Health operates a virtual health platform called the Digital Medical Home, providing a curated suite of digital solutions including primary care, behavioral health, at-home testing, and genetic screening. The platform is fully customizable to meet the needs of specific populations and enables patients to engage with physicians, receive personalized care, and monitor health remotely. Recuro serves payers, employers, and providers and positions itself to lower costs while improving access and outcomes as care shifts from traditional in-person settings to wherever patients and data are located. The company launched in March 2021 and is led by founder and CEO Michael Gorton. Recuro announced a convertible note financing co-led by ARCH Venture Partners and Cortado Ventures to fund its ongoing acquisition strategy and support continued growth. Cortado’s involvement marks its third investment in the company, signaling continued backer support. Recuro Health operates a customizable virtual health platform that bundles digital solutions from primary care and behavioral health to at-home testing and genetic screening. Its platform is designed to support payers, employers and providers and to create a personalized, holistic digital medical home that enables population-health and outcomes-focused care. Since launching in March 2021, Recuro has developed offerings including a widely adopted COVID-19 rapid testing solution used by employers and government customers. The company says its solutions enable earlier interventions, supplement in-person care, and provide detailed member health mosaics for risk stratification and diagnostics. Recuro plans to use the Series A proceeds to execute an acquisition strategy, expand marketing, and further build on growth since launch. Financially, Recuro announced a $15 million Series A led by ARCH Venture Partners with follow-on support from seed investors OLSF Ventures, Cortado Ventures, 1843 Capital and Sage Venture Partners. Recuro Health offers an integrated digital health platform that combines digital health tools with a patient-centered medical home, leveraging analytics and services to support patients across their entire health journeys. The company provides digital and virtual services that aggregate data to direct users to effective and efficient offerings, and evaluates outcomes and compliance to generate appropriate referrals and recommendations. Recuro says it is focused on empowering patients with tools, education and guidance to live healthier, longer and happier lives. Leadership includes Michael Gorton, founding CEO of Teladoc, alongside Teladoc's original CTO and marketing team, and additions such as Jay Sanders, MD. The company is building infrastructure and partnerships to support care delivery in every setting and to minimize the need for acute, episodic care. Recuro serves employers, providers and managed care organizations and plans to follow its current close with a larger funding round to accelerate growth.